Timmy Garde Named Chief Growth Officer of Ardelis Health

Ardelis Health, a healthcare strategic marketing agency and consulting firm partnering with innovators that discover, differentiate, and launch important therapies, today announced the appointment of industry veteran Timmy Garde as Chief Growth Officer.

“We are thrilled to welcome Timmy to the Ardelis leadership team. With his extensive industry experience and strategic perspective, he is the natural fit for this role,” said Jim Moran, co-founder and managing partner of Ardelis. “We are fortunate to work with innovative start-up and mid-stage biopharma companies that are developing vaccines and medicines for rare diseases, cancer, specialty therapeutic areas, and other patient needs, as well as partnering with diagnostic and medical device companies.”

Moran concluded, “We are committed to expanding our capabilities alongside them to support their efforts in advancing lifesaving solutions. Timmy will play a key role in evolving our services to meet the full business and marketing needs of our expanding client roster, and our new branding and website reflect these exciting changes to our team and offerings.”

Mr. Garde has more than 30 years’ experience in healthcare communication and business operations. In his most recent role, he served as Chief Innovation Leader at LevLane Advertising, where he drove breakthrough product launches and directed teams in U.S. Food and Drug Administration (FDA) approvals, compliance, marketing, and partnerships. Prior to that, Mr. Garde held the position of Chief Operating Officer at Calcium USA, where he was an early adopter of emerging digital healthcare trends and market impact, guiding new communications strategies for specialty pharma products, rare diseases, and more.

In addition to these roles, Mr. Garde is a force in the life sciences industry and a dedicated volunteer. He has launched and moderated annual Leaders in Life Sciences roundtable discussions and has mentored thousands of students at Penn State’s Smeal College of Business to support the next generation of marketing leaders. He was recently awarded the 2023 Smeal College of Business Service Award.

“I’m excited to join Ardelis and lead the next phase of our growth,” said Garde. “Our goal is to extend our marketing practice and provide unparalleled support to our clients’ executive and marketing teams by staying ahead of the curve and providing industry insights that can change the landscape. Together, we will help advance new medicines, diagnostics, medical devices, health technology, and digital healthcare products to make a powerful difference in the world and improve global health.”

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.